Egyesült Államok - angol - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - cephapirin benzathine (unii: 90g868409o) (cephapirin - unii:89b59h32vn) - cephapirin 300 mg in 10 ml - for the treatment of mastitis in dairy cows during the dry period. tomorrow has been shown by extensive clinical studies to be efficacious in the treatment of mastitis in dry cows, when caused by streptococcus agalactiae and staphylococcus aureus including penicillin-resistant strains. treatment of the dry cow with tomorrow is indicated in any cow known to harbor any of these organisms in the udder at drying off. indicaciones para el tratamiento de mastitis bovina durante el período seco. extensos estudios clínicos han demostrado que tomorrow es eficaz en el tratamiento de la mastitis en vacas secas, cuando ésta es causada por el streptococcus agalactiae y el staphylococcus aureus, incluyendo cepas resistentes a la penicilina. el tratamiento de la vaca seca con tomorrow es recomendado para cualquier vaca que se sepa alberga a cualquiera de estos organismos en la ubre al momento del período de secado. not for human use. este producto no es para administrarse en humanos.

Egyesült Államok - angol - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - cephapirin benzathine (unii: 90g868409o) (cephapirin - unii:89b59h32vn) - for the treatment of mastitis in dairy cows during the dry period. tomorrow has been shown by extensive clinical studies to be efficacious in the treatment of mastitis in dry cows, when caused by streptococcus agalactiae and staphylococcus aureus including penicillin-resistant strains. treatment of the dry cow with tomorrow is indicated in any cow known to harbor any of these organisms in the udder at drying off. indicaciones para el tratamiento de mastitis bovina durante el período seco. extensos estudios clínicos han demostrado que tomorrow es eficaz en el tratamiento de la mastitis en vacas secas, cuando ésta es causada por el streptococcus agalactiae y el staphylococcus aureus, incluyendo cepas resistentes a la penicilina. el tratamiento de la vaca seca con tomorrow es recomendado para cualquier vaca que se sepa alberga a cualquiera de estos organismos en la ubre al momento del período de secado.

Egyesült Államok - angol - NLM (National Library of Medicine)

stearns packaging corporation - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l), didecyldimonium chloride (unii: jxn40o9y9b) (didecyldimonium - unii:z7f472xqpa) - chlorhexidine gluconate 0.35 l in 100 l - take time observe label directions first-aid: eyes: if contact with eyes occurs, flush with plenty of cool water for 15 minutes. consult a physician. internal: may be harmful if swallowed. if ingested, drink large amounts of water. do not induce vomiting. get medical attention immediately. primeros auxilios: ojos: si ocurre contacto con los ojos, lavar con abundante agua fría durante 15 minutos. consulte a un médico. interno: puede ser nocivo en caso de ingestión. beba grandes cantidades de agua si se ingiere este producto. no induzca el vómito. obtenga atención médica inmediatamente. 24 hour emergency contact 24 horas servico telefónico de repuesta a emergencies: 1-800-255-3924

Egyesült Államok - angol - NLM (National Library of Medicine)

gojo industries, inc. - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - antiseptic if you are allergic to chlorhexidine gluconate or any other ingredients si es alérgico al gluconato de chlorhexidina o a cualquier otro ingrediente keep out of eyes, ear and mouth. may cause serious and permenant eye injury if placed or kept in the eye during surgical procedures or may cause deafness when instilled in the middle of the ear through perforated eardrums. if solution should contact these areas, rinse out promptly and thoroughly with water. evite el contacto con los ojos, oídos, y boca. puede causar daño ocular serio y permanente si se coloca o permanece en el ojo durante procedimientos quirúrgicos o puede causar sordera si se instila en el oído medio a través de tímpano perforado. si la solución llegara a tener contacto con estas àreas, enjuague lo más pronto posible con suficiente agua. irrititation, sensitization or allergic reaction occurs. these may be signs of a serious condition. reacciones de irritación, sensibilización o reacciones alérgicas aparecen. estos son signos de una co

Egyesült Államok - angol - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - omeprazole magnesium (unii: 426qfe7xlk) (omeprazole - unii:kg60484qx9) - omeprazole 10 mg - prilosec is indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within four weeks. some patients may require an additional four weeks of therapy. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. triple therapy prilosec in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate h. pylori in adults. dual therapy prilosec in combination with clarithromycin is indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate h. pylori in adults. among patients who fail therapy, prilosec with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. in patients who fail therapy, susceptibility testing should be done. if resistance to clarithromycin is demonstrated or susceptibility testing is not pos

Egyesült Államok - angol - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole 15 mg - lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see clinical studies (14.1)] . triple therapy: lansoprazole/amoxicillin/clarithromycin lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14.2)]. please refer to the full prescribing information for amoxicillin and clarithromycin. dual therapy: lansoprazole/amoxicillin lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in adults for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) who

Egyesült Államok - angol - NLM (National Library of Medicine)

actavis pharma, inc. - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole 15 mg - lansoprazole delayed-release capsules are indicated for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see clinical studies (14.1)]. triple therapy: lansoprazole delayed-release capsules/amoxicillin/clarithromycin   lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14.2)]. please refer to the full prescribing information for amoxicillin and clarithromycin. dual therapy: lansoprazole delayed-release capsules/amoxicillin   lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated  in adults  for the treatment of patients with h. pylori infection and duodenal ulcer disease (active

Egyesült Államok - angol - NLM (National Library of Medicine)

remedyrepack inc. - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole 30 mg - prevacid and prevacid solutab are indicated in adults for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer [see clinical studies (14.1)]. triple therapy: prevacid or prevacid solutab/amoxicillin/clarithromycin prevacid or prevacid solutab in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14.2)]. please refer to the full prescribing information for amoxicillin and clarithromycin. dual therapy: prevacid or prevacid solutab/amoxicillin prevacid or prevacid solutab in combination with amoxicillin as dual therapy is indicated in adults for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer

Egyesült Államok - angol - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - rabeprazole sodium 20 mg - rabeprazole sodium delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (gerd). for those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium may be considered. rabeprazole sodium delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (gerd maintenance). controlled studies do not extend beyond 12 months. rabeprazole sodium delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks. rabeprazole sodium delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. most patients heal within four weeks. rabeprazole sodium delayed-release t

Egyesült Államok - angol - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - pantoprazole sodium  delayed-release tablets are indicated for: pantoprazole sodium  delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (ee). for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole sodium  delayed-release tablets may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole sodium  delayed-release tablets are indicated for maintenance of healing of ee and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole sodium  delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome. teratogenic effects pregnancy category c  repr